- Home
- NIM vs KLRS Comparison
NIM vs KLRS Comparison
Compare NIM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIM | KLRS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 113.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NIM | KLRS |
|---|---|---|
| Price | $9.24 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 13.0K | ★ 71.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.07 | $2.37 |
| 52 Week High | $9.94 | $11.88 |
Technical Indicators
Market Signals| Indicator | NIM | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 49.50 |
| Support Level | $9.21 | $3.92 |
| Resistance Level | $9.45 | $4.40 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 16.86 | 62.77 |
Price Performance
Historical ComparisonAbout NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued. The fund has single operating segment.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.